Hi @ch1ch0 thanks for looking any way.
I don’t mind saying what I see in them at all …
I think Organigram is very well placed for longer term growth. Looking at the stats at the moment it does look terrible, but then show me a really credible cannabis stock that doesn’t right now
Unlike it’s nearest competitors who’ve aggressively gone on buy out binges to scale production, Organigram have been perfecting their on campus facility to turn out one of the lowest cost of production yields in the business, whilst also producing some of the finest quality, award winning plants, a sure way to keep and expand customer base.
Recreational weed aside, the company focuses on Med grade produce and has signed deals with Israeli firm Canndoc, giving access to European and Israeli markets. Also bought into Alpha-Cannabis, medicinal cannabis producer in the worlds biggest market for pharmaceutical grade cannabis, Germany.
OrganiGram has been one of the few major weed growers to run its business as a consumer packaged goods company right from the start. The company has placed a premium on growing great weed in a cost-efficient way since its inception. The net result is that OrganiGram has one of the lowest costs of production, a “better-than-many” balance sheet, and a well-earned reputation as a top-level grower. Many of OrganiGram’s peers, by contrast, are now facing serious liquidity issues because of their overly aggressive expansion plans.
There’s going to be many bankruptcies/closures of weed companies in the coming year, it’ll take this for any pot company to really expand like the initial startups, I think this company is in a great place to exploit this.
Trying to find a broker that sells the stock to UK investors is proving a challenge though
$1.31 I think is a steal compared to the longer term upside.